Summary & Overview
HCPCS J9031: BCG Intravesical Instillation per Administration
HCPCS Level II code J9031 identifies a single instillation of intravesical Bacillus Calmette-Guérin (BCG), a standard intravesical immunotherapy used primarily in the management of non–muscle invasive bladder cancer. Nationally, accurate coding of BCG instillations affects quality reporting, patient access to specialty therapy, and claims processing for outpatient and physician-administered drug services. The code is relevant across hospital outpatient departments, ambulatory infusion centers, and urology clinics where intravesical treatments are delivered.
This publication covers payer handling and coverage context for major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9031 represents, typical sites of service, and the clinical context for intravesical BCG. The report also summarizes benchmark and policy-relevant considerations that influence reimbursement and authorization workflows. Information on modifiers, related codes, ICD-10 mappings, and provider billing considerations is noted where available; if specific details were not provided in the source input, the publication indicates that those data are not available.
Intended for billing professionals, practice managers, and health policy analysts, this summary clarifies the clinical and billing purpose of HCPCS Level II code J9031 and outlines the practical coverage landscape among major payers.
Billing Code Overview
HCPCS Level II code J9031 represents BCG (intravesical) per instillation. This code describes the intravesical administration of Bacillus Calmette-Guérin (BCG) directly into the bladder for therapeutic purposes.
-
Service type: Intravesical instillation (therapeutic medication administration into the bladder)
-
Typical site of service: Ambulatory infusion centers, hospital outpatient departments, physician offices with urology services, and specialty clinics where intravesical therapies are provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a history of non‑muscle invasive bladder cancer (high‑grade Ta/T1 carcinoma) presents to the urology infusion suite for intravesical immunotherapy. The patient has undergone transurethral resection of bladder tumor (TURBT) and is scheduled for intravesical administration of Bacillus Calmette‑Guérin (BCG) as part of induction therapy. Pre‑visit nursing assessment confirms recent voiding, no active urinary tract infection, and no systemic symptoms. The patient is positioned supine on the procedure table; a trained nurse or advanced practice provider inserts a lubricated catheter into the bladder under sterile technique and drains residual urine. The prescribed dose of J9031 (BCG, intravesical, per instillation) is instilled into the bladder via the catheter; the catheter is removed and the patient is instructed to retain the instilled agent for the prescribed dwell time (typically 1–2 hours) and to void in a seated position. Observation for immediate adverse reactions occurs in the infusion suite for a short period. Documentation includes indication, consent, lot number and expiration of the BCG vial, instilled volume, dwell time instructions, patient tolerance, and discharge instructions regarding infection control and when to seek urgent care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of the procedure |